Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 plus exemestane and everolimus versus placebo plus exemestane and everolimus in hormone receptor-positive HER2-negative metastatic breast cancer with bone metastases
NL-OMON44036Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer and bone metastases comparing Radium-223 + exemestane + everolimus with Placebo + exemestane + everolimus (2 arms). Primary endpoint: Symptomatic skeletal event-free survival. Started Jun 2015; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on NL-OMON44036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44036.